<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM9450</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-9450</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Studies</subject></subj-group></article-categories><title-group><article-title>Нарушения углеводного и жирового обмена у женщин с первичным гиперпаратиреозом: результаты поперечного исследования</article-title><trans-title-group xml:lang="en"><trans-title>Carbohydrate and lipid metabolism disorders in women with primary hyperparathyroidism: results of cross-sectional study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9717-9742</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мокрышева</surname><given-names>Наталья Георгиевна</given-names></name><name name-style="western" xml:lang="en"><surname>Mokrysheva</surname><given-names>Natalia G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">nm70@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8916-7346</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Добрева</surname><given-names>Екатерина Александровна</given-names></name><name name-style="western" xml:lang="en"><surname>Dobreva</surname><given-names>Ekaterina A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., с.н.с.</p></bio><bio xml:lang="en"><p>MD, PhD, senior research associate</p></bio><email xlink:type="simple">dobrevae@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1341-0397</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мирная</surname><given-names>Светлана Сергеевна</given-names></name><name name-style="western" xml:lang="en"><surname>Mirnaya</surname><given-names>Svetlana S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>н.с.</p></bio><bio xml:lang="en"><p>MD, research associate</p></bio><email xlink:type="simple">svetlanamirnaya@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8175-7886</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дедов</surname><given-names>Иван Иванович</given-names></name><name name-style="western" xml:lang="en"><surname>Dedov</surname><given-names>Ivan I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">dedov@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;Национальный медицинский исследовательский центр эндокринологии&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;Endocrinology Research Centre&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>08</day><month>04</month><year>2019</year></pub-date><volume>22</volume><issue>1</issue><fpage>8</fpage><lpage>13</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мокрышева Н.Г., Добрева Е.А., Мирная С.С., Дедов И.И., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Мокрышева Н.Г., Добрева Е.А., Мирная С.С., Дедов И.И.</copyright-holder><copyright-holder xml:lang="en">Mokrysheva N.G., Dobreva E.A., Mirnaya S.S., Dedov I.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/9450">https://www.dia-endojournals.ru/jour/article/view/9450</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Смертность среди пациентов с первичным гиперпаратиреозом (ПГПТ) выше средней по популяции, что связывают с повышением сердечно-сосудистых рисков. Поскольку ключевую роль в развитии последних играют наличие избыточной массы тела, атерогенный эффект нарушений липидного спектра крови, нарушения углеводного обмена и развитие инсулинорезистентности (ИР), исследование состояния жирового и углеводного обмена у пациентов с ПГПТ поможет пролить свет на патогенетические механизмы заболевания и, возможно, дополнить алгоритм выбора тактики лечения пациентов.</p></sec><sec><title>Цель</title><p>Цель. Изучение распространенности нарушений углеводного и жирового обмена среди пациентов с ПГПТ, выявление взаимосвязей этих нарушений с показателями минерального обмена.</p></sec><sec><title>Методы</title><p>Методы. В наблюдательном моноцентровом поперечном контролируемом исследовании приняли участие 256 женщин: 220 с ПГПТ и 36 относительно здоровых, сопоставимых по возрасту. Группа женщин с ПГПТ была разделена на 2 подгруппы — с манифестной и мягкой формой ПГПТ. Для верификации формы ПГПТ проводили ультразвуковое исследование околощитовидных желез и почек, двухэнергетическую рентгеновскую абсорбциометрию (DEXA), биохимические исследования (измерение концентрации общего и ионизированного кальция, фосфора, активности щелочной фосфатазы) и оценку концентрации паратгормона. Взаимосвязь формы ПГПТ с динамикой массы тела оценивали ретроспективно по данным анкетирования. У 109 участниц с ПГПТ (у 82 с манифестным и у 27 с мягким ПГПТ) и у всей группы контроля были оценены биохимические и гормональные показатели жирового (липидный спектр крови) и углеводного обмена (содержание иммунореактивного инсулина, индекс инсулинорезистентности (ИР) HOMA, наличие нарушения гликемии натощак, нарушения толерантности к глюкозе, сахарного диабета 2 типа).</p></sec><sec><title>Результаты</title><p>Результаты. Манифестная форма ПГПТ была ассоциирована с низким индексом массы тела (ИМТ), а мягкая форма – с высоким ИМТ. Отмечено, что постпрандиальная гликемия в ходе орального текста на толерантность к глюкозе при манифестной форме ПГПТ значимо выше, чем при мягкой форме ПГПТ (р=0,036). Содержание иммунореактивного инсулина при манифестной форме не коррелировало с концентрацией паратгормона, но положительно коррелировало с концентрацией ионизированного кальция в крови (r=0,31; p=0,006). У пациенток с ПГПТ обнаружена прямая положительная корреляция ИМТ с индексом ИР НОМА (r=0,67; p&lt;0,001). Показано, что у пациенток с ПГПТ повышено содержание липопротеинов низкой плотности в крови, и фактические показатели концентрации липидов в крови связаны с состоянием фильтрационной функции почек.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные данные подтверждают связь нарушений фосфорно-кальциевого обмена при ПГПТ с нарушениями углеводного и жирового обмена. Для детального изучения причинно-следственных связей нарушений минерального, углеводного и жирового обмена при ПГПТ целесообразны дальнейшие проспективные контролируемые исследования.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background: Patients with primary hyperparathyroidism (PHPT) have increased mortality risk predominantly attributed to cardiovascular disease. Taking the risk factors for cardiovascular disease into account, such as overweight, atherogenic dyslipidaemia, carbohydrate metabolism disorders and insulin resistance (IR), investigation on the the study of the state of carbohydrate and lipid metabolism in patients with PHPT will help to shed light on the pathogenic mechanisms of the disease and, perhaps, to complement the algorithm for selecting treatment strategies for patients with PHPT.</p></sec><sec><title>Aims</title><p>Aims: To study the prevalence of carbohydrate and lipid metabolism disorders among patients with PHPT and to identify the relationship between these two disorders with the indicators of mineral metabolism.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: A case-control study of a total of age-matched 256 female patients, 220 patients with PHPT and 36 healthy individuals. The group patients with PHPT were sub-divided into two groups, symptomatic and mild form of PHPT. To verify the form of PHPT, ultrasound examinations of the parathyroid glands and kidneys, two-energy x-ray absorptiometry, biochemical studies (concentration of total and ionised calcium, serum phosphorus and the activity of alkaline phosphatase) and assessment of parathyroid hormone concentration were performed. The relationship between form of PHPT and body weight were evaluated retrospectively according to the survey. Among the 109 participants with PHPT (symptomatic PHPT: 82 patients; mild PHPT: 27 patients) and healthy individuals, the biochemical and hormonal parameters of fat (lipid spectrum of blood) and carbohydrate metabolism (content of immunoreactive insulin, HOMA index, presence of fasting glycemia disorder, glucose tolerance disorders and type 2 diabetes mellitus) were evaluated.</p></sec><sec><title>Results</title><p>Results: The symptomatic PHPT was associated with low body mass index (BMI) while the mild PHPT with high BMI. During an oral glucose tolerance test, the postprandial glycemia in symptomatic PHPT was significantly higher than that in mild PHPT (p = 0.036). The content of immunoreactive insulin in the symptomatic PHPT was not correlated with the concentration of parathyroid hormone, but positively correlated with the concentration of ionised calcium in the blood (r = 0.31; p = 0.006). Patients with PHPT showed a direct positive correlation between BMI and IR index (r = 0.67; p &lt; 0.001). It is shown that patients with PHPT have increased LDL content in the blood, and the actual blood lipid concentration is associated with the state of kidney function.</p></sec><sec><title>Conclusions</title><p>Conclusions: The obtained data confirm the relationship between phosphorus–calcium metabolism disorders in PHPT and carbohydrate and lipid metabolism disorders. Prospective, controlled studies are warranted to better elucidate the causal relationships of mineral, carbohydrate and fat metabolism disorders in PHPT.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>первичный гиперпаратиреоз</kwd><kwd>инсулинорезистентность</kwd><kwd>липидный обмен</kwd><kwd>паратгормон</kwd><kwd>гиперкальциемия</kwd><kwd>постпрандиальный ответ глюкозы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>primary hyperparathyroidism</kwd><kwd>insulin resistance</kwd><kwd>lipid metabolism</kwd><kwd>parathyroid hormone</kwd><kwd>hypercalcemia</kwd><kwd>postprandial response</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вороненко И.В., Сыркин А.Л., Рожинская Л.Я., Мельниченко Г.А. Гиперпаратиреоз и патология сердечно-сосудистой системы // Остеопороз и остеопатиии. — 2006. — Т. 9. — №2. — С. 33-41. [Voronenko IV, Syrkin AL, Rozhinskaya LY, Mel'nichenko GA. Hyperparatirosis and cardiovascular system pathology. Osteoporosis and bone diseases. 2006;9(2):33-41. (In Russ.)] doi: https://doi.org/10.14341/osteo2006233-41</mixed-citation><mixed-citation xml:lang="en">Вороненко И.В., Сыркин А.Л., Рожинская Л.Я., Мельниченко Г.А. Гиперпаратиреоз и патология сердечно-сосудистой системы // Остеопороз и остеопатиии. — 2006. — Т. 9. — №2. — С. 33-41. [Voronenko IV, Syrkin AL, Rozhinskaya LY, Mel'nichenko GA. Hyperparatirosis and cardiovascular system pathology. Osteoporosis and bone diseases. 2006;9(2):33-41. (In Russ.)] doi: https://doi.org/10.14341/osteo2006233-41</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Мокрышева Н.Г. Первичный гиперпаратиреоз. Эпидемиология, клиника, современные принципы диагностики и лечения: Дис. … д-ра мед. наук. — М.; 2011. [Mokrysheva NG. Pervichnyy giperparatireoz. Epidemiologiya, klinika, sovremennye printsipy diagnostiki i lecheniya.[dissertation] Moscow; 2011. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Мокрышева Н.Г. Первичный гиперпаратиреоз. Эпидемиология, клиника, современные принципы диагностики и лечения: Дис. … д-ра мед. наук. — М.; 2011. [Mokrysheva NG. Pervichnyy giperparatireoz. Epidemiologiya, klinika, sovremennye printsipy diagnostiki i lecheniya.[dissertation] Moscow; 2011. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest. 2003;26(11):1136-1142. doi: https://doi.org/10.1007/BF03345264</mixed-citation><mixed-citation xml:lang="en">Procopio M, Borretta G. Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest. 2003;26(11):1136-1142. doi: https://doi.org/10.1007/BF03345264</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tassone F, Procopio M, Gianotti L, et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet Med. 2009;26(10):968-973. doi: https://doi.org/10.1111/j.1464-5491.2009.02804.x</mixed-citation><mixed-citation xml:lang="en">Tassone F, Procopio M, Gianotti L, et al. Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet Med. 2009;26(10):968-973. doi: https://doi.org/10.1111/j.1464-5491.2009.02804.x</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas A, Kautzky-Willer A. Diabetes in Hyperparathyroidism. In: Ghigo E, Porta M, editors. Diabetes Secondary to Endocrine and Pancreatic Disorders. Front Diabetes. Vol 22. Basel: Karger; 2014. p. 92-100.</mixed-citation><mixed-citation xml:lang="en">Thomas A, Kautzky-Willer A. Diabetes in Hyperparathyroidism. In: Ghigo E, Porta M, editors. Diabetes Secondary to Endocrine and Pancreatic Disorders. Front Diabetes. Vol 22. Basel: Karger; 2014. p. 92-100.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Temizkan S, Kocak O, Aydin K, et al. Normocalcemic hyperparathyroidism and insulin resistance. Endocr Pract. 2015;21(1):23-29. doi: https://doi.org/10.4158/EP14195.OR</mixed-citation><mixed-citation xml:lang="en">Temizkan S, Kocak O, Aydin K, et al. Normocalcemic hyperparathyroidism and insulin resistance. Endocr Pract. 2015;21(1):23-29. doi: https://doi.org/10.4158/EP14195.OR</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Curione M, Letizia C, Amato S, et al. Increased risk of cardiac death in primary hyperparathyroidism: what is a role of electrical instability? Int J Cardiol. 2007;121(2):200-202. doi: https://doi.org/10.1016/j.ijcard.2006.08.072</mixed-citation><mixed-citation xml:lang="en">Curione M, Letizia C, Amato S, et al. Increased risk of cardiac death in primary hyperparathyroidism: what is a role of electrical instability? Int J Cardiol. 2007;121(2):200-202. doi: https://doi.org/10.1016/j.ijcard.2006.08.072</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">McCarty MF, Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses. 2003;61(5-6):535-542. doi: https://doi.org/10.1016/s0306-9877(03)00227-5</mixed-citation><mixed-citation xml:lang="en">McCarty MF, Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses. 2003;61(5-6):535-542. doi: https://doi.org/10.1016/s0306-9877(03)00227-5</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Delfini E, Petramala L, Caliumi C, et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism. 2007;56(1):30-36. doi: https://doi.org/10.1016/j.metabol.2006.08.019</mixed-citation><mixed-citation xml:lang="en">Delfini E, Petramala L, Caliumi C, et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism. 2007;56(1):30-36. doi: https://doi.org/10.1016/j.metabol.2006.08.019</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lacour B, Roullet J-B, Liagre A-M, et al. Serum Lipoprotein Disturbances in Primary and Secondary Hyperparathyroidism and Effects of Parathyroidectomy. Am J Kidney Dis. 1986;8(6):422-429. doi: https://doi.org/10.1016/s0272-6386(86)80169-x</mixed-citation><mixed-citation xml:lang="en">Lacour B, Roullet J-B, Liagre A-M, et al. Serum Lipoprotein Disturbances in Primary and Secondary Hyperparathyroidism and Effects of Parathyroidectomy. Am J Kidney Dis. 1986;8(6):422-429. doi: https://doi.org/10.1016/s0272-6386(86)80169-x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Christensson T, Einarsson K. Serum lipids before and after parathyroidectomy in patients with primary hyperparathyroidism. Clinica Chimica Acta. 1977;78(3):411-415. doi: https://doi.org/10.1016/0009-8981(77)90074-2</mixed-citation><mixed-citation xml:lang="en">Christensson T, Einarsson K. Serum lipids before and after parathyroidectomy in patients with primary hyperparathyroidism. Clinica Chimica Acta. 1977;78(3):411-415. doi: https://doi.org/10.1016/0009-8981(77)90074-2</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Erem C, Kocak M, Hacihasanoglu A, et al. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. Exp Clin Endocrinol Diabetes. 2008;116(10):619-624. doi: https://doi.org/10.1055/s-2008-1065365</mixed-citation><mixed-citation xml:lang="en">Erem C, Kocak M, Hacihasanoglu A, et al. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. Exp Clin Endocrinol Diabetes. 2008;116(10):619-624. doi: https://doi.org/10.1055/s-2008-1065365</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47(10):1643-1649. doi: https://doi.org/10.2337/diabetes.47.10.1643</mixed-citation><mixed-citation xml:lang="en">Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47(10):1643-1649. doi: https://doi.org/10.2337/diabetes.47.10.1643</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2005;90(3):1525-1530. doi: https://doi.org/10.1210/jc.2004-1891</mixed-citation><mixed-citation xml:lang="en">Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab. 2005;90(3):1525-1530. doi: https://doi.org/10.1210/jc.2004-1891</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stampfer MJ. A Prospective Study of Triglyceride Level, Low-Density Lipoprotein Particle Diameter, and Risk of Myocardial Infarction. JAMA. 1996;276(11):882. doi: https://doi.org/10.1001/jama.1996.03540110036029</mixed-citation><mixed-citation xml:lang="en">Stampfer MJ. A Prospective Study of Triglyceride Level, Low-Density Lipoprotein Particle Diameter, and Risk of Myocardial Infarction. JAMA. 1996;276(11):882. doi: https://doi.org/10.1001/jama.1996.03540110036029</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Krauss RM. Atherogenicity of Triglyceride-Rich Lipoproteins. Am J Cardiol. 1998;81(4):13B-17B. doi: https://doi.org/10.1016/s0002-9149(98)00032-0</mixed-citation><mixed-citation xml:lang="en">Krauss RM. Atherogenicity of Triglyceride-Rich Lipoproteins. Am J Cardiol. 1998;81(4):13B-17B. doi: https://doi.org/10.1016/s0002-9149(98)00032-0</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yener Ozturk F, Erol S, Canat MM, et al. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J. 2016;63(2):111-118. doi: https://doi.org/10.1507/endocrj.EJ15-0392</mixed-citation><mixed-citation xml:lang="en">Yener Ozturk F, Erol S, Canat MM, et al. Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr J. 2016;63(2):111-118. doi: https://doi.org/10.1507/endocrj.EJ15-0392</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the Incident Metabolic Syndrome in Adults: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27(3):788-793. doi: https://doi.org/10.2337/diacare.27.3.788</mixed-citation><mixed-citation xml:lang="en">Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the Incident Metabolic Syndrome in Adults: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27(3):788-793. doi: https://doi.org/10.2337/diacare.27.3.788</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Grundy SM, Hansen B, Smith SC, Jr., et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109(4):551-556. doi: https://doi.org/10.1161/01.CIR.0000112379.88385.67</mixed-citation><mixed-citation xml:lang="en">Grundy SM, Hansen B, Smith SC, Jr., et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109(4):551-556. doi: https://doi.org/10.1161/01.CIR.0000112379.88385.67</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor WH, Khaleeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev. 2001;17(3):175-180. doi: https://doi.org/10.1002/dmrr.199</mixed-citation><mixed-citation xml:lang="en">Taylor WH, Khaleeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev. 2001;17(3):175-180. doi: https://doi.org/10.1002/dmrr.199</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Schiffl H, Sitter T, Lang SM. Noradrenergic blood pressure dysregulation and cytosolic calcium in primary hyperparathyroidism. Kidney Blood Press Res. 1997;20(5):290-296. doi: https://doi.org/10.1159/000174161</mixed-citation><mixed-citation xml:lang="en">Schiffl H, Sitter T, Lang SM. Noradrenergic blood pressure dysregulation and cytosolic calcium in primary hyperparathyroidism. Kidney Blood Press Res. 1997;20(5):290-296. doi: https://doi.org/10.1159/000174161</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Haap M, Heller E, Thamer C, et al. Association of serum phosphate levels with glucose tolerance, insulin sensitivity and insulin secretion in non-diabetic subjects. Eur J Clin Nutr. 2006;60(6):734-739. doi: https://doi.org/10.1038/sj.ejcn.1602375</mixed-citation><mixed-citation xml:lang="en">Haap M, Heller E, Thamer C, et al. Association of serum phosphate levels with glucose tolerance, insulin sensitivity and insulin secretion in non-diabetic subjects. Eur J Clin Nutr. 2006;60(6):734-739. doi: https://doi.org/10.1038/sj.ejcn.1602375</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO; 1999.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO; 1999.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ремизов О.В. Инсулинорезистентность у детей. Гормонально-метаболические аспекты патогенеза, профилактика и лечение СД 2 типа: Автореф. дис. … д-ра мед. наук. — М.; 2005. [Remizov OV. Insulinorezistentnost' u detey. Gormonal'no-metabolicheskie aspekty patogeneza, profilaktika i lechenie SD 2 tipa. [dissertation] Moscow; 2005. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Ремизов О.В. Инсулинорезистентность у детей. Гормонально-метаболические аспекты патогенеза, профилактика и лечение СД 2 типа: Автореф. дис. … д-ра мед. наук. — М.; 2005. [Remizov OV. Insulinorezistentnost' u detey. Gormonal'no-metabolicheskie aspekty patogeneza, profilaktika i lechenie SD 2 tipa. [dissertation] Moscow; 2005. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Putnam R, Dhibar DP, Varshney S, et al. Effect of curative parathyroidectomy on insulin resistance. Indian J Endocrinol Metab. 2016;20(6):784-789. doi: https://doi.org/10.4103/2230-8210.192916</mixed-citation><mixed-citation xml:lang="en">Putnam R, Dhibar DP, Varshney S, et al. Effect of curative parathyroidectomy on insulin resistance. Indian J Endocrinol Metab. 2016;20(6):784-789. doi: https://doi.org/10.4103/2230-8210.192916</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Cvijovic G, Micic D, Kendereski A, et al. The effect of parathyroidectomy on insulin sensitivity in patients with primary hyperparathyroidism - an never ending story? Exp Clin Endocrinol Diabetes. 2015;123(6):336-341. doi: https://doi.org/10.1055/s-0035-1549906</mixed-citation><mixed-citation xml:lang="en">Cvijovic G, Micic D, Kendereski A, et al. The effect of parathyroidectomy on insulin sensitivity in patients with primary hyperparathyroidism - an never ending story? Exp Clin Endocrinol Diabetes. 2015;123(6):336-341. doi: https://doi.org/10.1055/s-0035-1549906</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor WH. The Prevalence of Diabetes Mellitus in Patients with Primary Hyperparathyroidism and Among Their Relatives. Diabet Med. 1991;8(7):683-687. doi: https://doi.org/10.1111/j.1464-5491.1991.tb01678.x</mixed-citation><mixed-citation xml:lang="en">Taylor WH. The Prevalence of Diabetes Mellitus in Patients with Primary Hyperparathyroidism and Among Their Relatives. Diabet Med. 1991;8(7):683-687. doi: https://doi.org/10.1111/j.1464-5491.1991.tb01678.x</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Dalberg K, Brodin LA, Juhlin-Dannfelt A, Farnebo LO. Cardiac function in primary hyperparathyroidism before and after operation. An echocardiographic study. Eur J Surg. 1996;162(3):171-176.</mixed-citation><mixed-citation xml:lang="en">Dalberg K, Brodin LA, Juhlin-Dannfelt A, Farnebo LO. Cardiac function in primary hyperparathyroidism before and after operation. An echocardiographic study. Eur J Surg. 1996;162(3):171-176.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
